garsorasib + benmelstobart + anlotinib

This combination therapy consists of garsorasib (also known as goselasib or D-1553), benmelstobart (TQB2450), and anlotinib (AL3818). It is currently being investigated as a first-line treatment for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer (NSCLC). Garsorasib is a potent and selective small-molecule inhibitor of the KRAS G12C mutation, which locks the protein in its inactive GDP-bound state to inhibit downstream oncogenic signaling. Benmelstobart is a humanized monoclonal antibody targeting programmed cell death ligand 1 (PD-L1), designed to block the PD-1/PD-L1 pathway and restore T-cell-mediated anti-tumor immunity. Anlotinib is a multi-targeted tyrosine kinase inhibitor that primarily inhibits VEGFR1/2/3, FGFR1/2/3/4, PDGFR alpha/beta, and c-Kit, thereby suppressing tumor angiogenesis and growth. The triple combination aims to provide a synergistic therapeutic effect by simultaneously targeting the driver mutation, the immune microenvironment, and tumor vascularization.

Other names

Goselasib + Benmelstobart + Anlotinib